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PREFACE 
  Aims and scope of the thesis 
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Malaria is one of the most significant parasitic diseases in the world.  Even with increased efforts 
focused on controlling the protozoan parasites as well as the mosquito vector, malaria still claims 
600,000 lives and affects 2 million people globally.   
Currently, artemisinins, in combination with other antimalarials, are the treatment of choice for 
severe malaria.  However, emerging resistance to artemisinins must be overcome.  Vaccines for 
prevention of infection would be very promising, but it is still currently under testing. 
Novel compounds are continuously being screened as potential antimalarials.  High-throughput 
screening technologies, as well as genomic revolution have been instrumental in accelerating the 
continuing efforts to search for new antimalarials.  Target compounds include naturally-
occurring and synthetic compounds, as both quinine, which is considered the oldest antimalarial, 
and artemisinin, were derived from plant extracts.  Extracts from plants in endemic areas are also 
very promising sources of new compounds.   
Extracts from marine sources like seaweeds, algae, and macroalgae are currently gaining 
popularity for their potential medical applications.  Sulfated polysaccharides like carrageenans 
and fucoidan, as well as, new classes of macrolides like diterpenes and bromophycolides have 
been shown to have antimalarial activities in vitro.  
In this study, the author describes the assessment of novel polysaccharides for their antimalarial 
effects in vitro and in vivo. 
The GENERAL INTRODUCTION provides the background on the etiologic agents of malaria, 
the Plasmodium parasites, their life cycle and the pathology of malaria.  It also touches on the 
approaches to the treatment and control of malaria, the current therapies and the challenges that 
must be faced.  It also provides information on the polysaccharides, namely, κ- and  λ-
carrageenans, gellan gum and gellan sulfate, that were used in these studies. 
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In CHAPTER 1, the author describes the synthesis of gellan sulfate, the sulfated derivative of 
gellan gum, oversulfated κ-carrageenan and hydrolyzed λ-carrageenan, the determination of the 
levels of sulfation of gellan sulfate and oversulfated κ-carrageenan, and the  in vitro assessment 
of their activities against P. falciparum and their cytotoxicity to 293T cells.  The anticoagulant 
activity of gellan sulfate, a novel anticoagulant was also assessed using APTT assays in vitro. 
In CHAPTER 2, the author assessed the in vivo effect of gellan sulfate on the growth of P. yoelii 
17XL and P. berghei ANKA in mice following the 4-day suppressive test.  
In CHAPTER 3, the author describes the endeavor to induce and confirm the development of 
experimental cerebral malaria by administration of λ-carrageenan in the BALB/c mouse infected 
with P. berghei ANKA. 
The GENERAL CONCLUSION discusses the thesis collectively and provides insights for future 
studies. 
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GENERAL INTRODUCTION 
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The etiological agents of malaria, the Plasmodium parasites, are obligate intracellular 
protozoa of the Apicomplexan family.  Members of this family of protozoans have the 
characteristic apical complex that possesses organelles involved in the invasion of host cells.  
Plasmodium species require mosquito primary hosts for sexual reproduction and vertebrate hosts 
for asexual reproduction and production of the gametocytes.  The female Anopheles mosquito 
also serves as vector that transmits the parasites to humans, non-human primates and rodents, 
while other species of mosquitoes like Culex spp. transmit the parasites to birds and rodents. 
The human malaria parasite, Plasmodium falciparum, is transmitted during the blood meal 
of an infected female Anopheles mosquito (Fig. 1).  P. falciparum sporozoites in the saliva of the 
mosquito are injected into the dermis.  Some sporozoites are transported to the liver via blood 
circulation, some are ingested by macrophages, while others go to the lymphatics, ending up in 
the spleen where they are presumably cleared.  Those that have migrated to the liver invade 
hepatocytes and produce daughter merozoites.  These daughter merozoites are then released into 
the bloodstream where these merozoites invade the red blood cells. In Plasmodium vivax and P. 
ovale infections, the parasite in the hepatocytes may not mature into a schizont immediately.  
This remains dormant in the liver as hypnozoite and that makes it difficult to diagnose and treat.  
[Igweh 2012]. 
Within the red blood cell, the merozoite develops into a ring-shaped form, then to a 
trophozoite form and later into schizont and produce new daughter merozoites.  The daughter 
merozoites are then released with the destruction of the red blood cell.  Along with the new 
merozoites, toxic materials are released into the bloodstream that triggers the host immune 
responses that manifest the clinical signs of the disease. Some merozoites differentiate into male 
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and female gametocytes. The gametocytes are taken up by an Anopheles mosquito when it feeds 
on an infected individual.  At the initial stages, the development of parasite occurs inside the 
blood bolus.  The gametocytes are later liberated from the red blood cells and form the gametes.  
The gametes fuse to give rise to the zygote and then into the ookinete. The motile ookinete 
crosses the midgut epithelium into the hemocoel, where it stays between the epithelial surface 
and the basal lamina then transforms into an oocyst.  The oocyst matures after 10-14 days and 
then releases sporozoites into the hemocoel.  The sporozoites will travel to the salivary glands, 
stay within, and then get released each time the mosquito feeds [Abraham 2004] allowing the 
cycle of transmission to continue.  
Infected red blood cells (iRBCs) of P. falciparum tend to form rosettes (Figure 2).  
Rosettes can cause vascular occlusion that contributes to the development of the severe 
complications of the disease such as cerebral malaria [Igweh 2012].  Cerebral malaria is one of 
the leading causes of death in young children despite rapid administration of chemotherapy [van 
der Heyde 2006].  The clinical features of human cerebral malaria (HCM) include neurological 
syndromes with patients in unrousable coma.  Seizures, retinopathy, and brainstem alterations 
due to increased intracranial pressure and swelling of the brain are also observed. [Renia 2012].   
Heparin, a highly sulfated glycosaminoglycan, can inhibit rosetting and cytoadherence of iRBCs 
in vitro [Xiao 1996].  It can also inhibit invasion of the erythrocytes by the Plasmodium 
merozoites [Wilson 2013].  It was at first used as adjunct therapy to malaria, but there was 
intracranial bleeding with heparin use and thus its use in clinical malaria has been discontinued 
[Igweh 2012]. 
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Another complication of P. falciparum is placental malaria.  Placental malaria is prevalent 
in primigravidae women especially in endemic countries.  The effects on the mother and the 
fetus would be abortion, stillbirth, premature delivery, and low birth weight of the infant.  In less 
severe cases, morbidity is presented by anemia and low birth weight of the child.  This is 
characterized by the presence of parasites in intervillous spaces along with leukocytes, adhering 
to chondroitin sulfate A (CSA), a glycosaminoglycan receptor present in the placenta [Achur 
2000; Matteelli 1997]. 
 Current antimalarial therapies target the blood stage intraerythrocytic Plasmodium 
parasite [Wilson, 2013].  P. falciparum gametocytes are relatively insensitive to most 
antimalarials, except artemisinins and primaquine.  That is why artemisinin combination 
therapies (ACTs) have the advantage of reducing both sexual and asexual stages of P. 
falciparum.   Primaquine can effectively kill gametocytes thereby preventing transmission.  
However, primaquine also causes methemoglobinemia and hemolysis, which is disadvantageous 
to the malaria patient [Barnes 2012]. 
 Parasite resistance to antimalarial drugs is a major hurdle in malaria control and 
elimination.   Resistance to antimalarials are associated with return of illnesss, anemia, increased 
gametocyte carriage, which could promote the transmission of resistant parasites.  Widespread 
resistance has been reported for chloroquine and sulfadoxine-pyrimethamine monotherapies. 
Recently, reported resistance to artemisinin, as shown by prolonged parasite clearance times 
even with adequate or increased drug exposure, along the Thai-Cambodian border alarmed the 
malaria control community [Barnes 2012; Grellier 2012] 
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 With concerted efforts towards eliminating malaria which include greater distribution of 
insecticide-treated mosquito nets, increased use of residual spraying, use of rapid diagnostic tests 
services for early diagnosis and treatment of the disease with ACTs, there has been a decline in 
the morbidities and mortalities in sub-Saharan Africa [Kweka, 2013].  Other endeavors are 
dedicated to researches on elucidating molecular mechanisms for developing new drugs and 
vaccines. 
 There is growing interest in compounds from novel sources, such as seaweeds, and 
marine invertebrates as potential drugs.  Sulfated polysaccharides derived from seaweeds such as 
fucoidan [Chen 2009], and carrageenans (Figure 3A, 3B, and 3C) [Adams, 2005], and diterpenes 
[Stout 2010] from algae have been assessed for their antimalarial effects.  Fucoidan [Chen 2009] 
and the 3 types of carrageenan (namely, λ, ι, and κ) [Adams 2005] inhibit the in vitro growth and 
invasion of red blood cells by P. falciparum.   Although  the underlying mechanism how these 
sulfated polysaccharides work is still unclear, it may be similar to the action of heparin.  Heparin 
and heparan sulfate interact with merozoite proteins [Zhang 2013; Kobayashi 2013] such as the 
merozoite surface protein 1 [Boyle 2010] and EBA-140 [Kobayashi 2010].   
 κ-carrageenan has been modified by acetylation, sulfation, and phosphorylation [Yuan 
2005]. These κ-carrageenan derivatives were found to be active against tumor cells [Yuan 2006; 
Yuan 2011], bacteria [Wang 2011] and viruses, like influenza virus [Wang 2011; Tang 2013], 
and human immunodeficiency virus [Vlieghe 2002].  
 Gellan gum is a microbial polysaccharide produced by the bacterium Sphingomonas 
(Pseudomonas) elodea (ATCC 31461).  It is a thermoreversible gel, that is currently utilized as 
drug vehicle, food additive, component of personal care products, and microbiological media. Its 
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basic repeating unit is a tetrasaccharide, consisting of two glucose (Glc) residues, one glucuronic 
acid (GlcA), and one rhamnose (Rha) residue: [→3)-β-D-Glcp-(1→4)-β-D-GlcpA-(1→4)-β-D-
Glcp-(1→4)-α-L-Rhap-(1→]  [Ogaji 2012; Rinaudo 2000; Shah 2007; Goncalves 2009].  Gellan 
gum has been reported to be safe for internal use [Shah 2007].  Gellan sulfate is the sulfated 
derivative of gellan gum [Miyamoto 2001] that possesses anticoagulant activities similar to 
heparin.  These novel sulfated polysaccharides can make interesting antimalarial candidates. 
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Figure legends 
Figure 1.  The life cycle of the Plasmodium falciparum parasite.  Plasmodium falciparum, is 
transmitted during the blood meal of an infected female Anopheles mosquito.  P. falciparum 
sporozoites in the saliva of the mosquito are injected into the dermis and migrate to the liver 
where they invade hepatocytes and produce daughter merozoites.  The daughter merozoites are 
released into the bloodstream where they invade the red blood cells. Within the red blood cell, 
the merozoite undergoes cell division and develops into a ring, trophozoite and schizont forms, 
finally producing new daughter merozoites.  The daughter merozoites are released with the 
destruction of the red blood cell. Some merozoites differentiate into male and female 
gametocytes that are taken up by an Anopheles mosquito when it feeds on the infected 
individual.  Inside the mosquito gut, the gametocytes are free from the red blood cells and form 
the gametes.  The gametes fuse giving rise to the zygote and then into the ookinete. The motile 
ookinete crosses the midgut epithelium into the hemocoel, where it stays between the epithelial 
surface and the basal lamina then transforms into an oocyst.  The oocyst matures after 10-14 
days and then releases sporozoites into the hemocoel.  The sporozoites will travel to the salivary 
glands, stay within, and then get released each time the mosquito feeds allowing the cycle of 
transmission to continue.  
 
Figure 2. Rosetting, sequestration and cytoadhesion of Plasmodium falciparum infected red 
blood cells. Rosetting, sequestration and cytoadherence to endothelial cells can cause vascular 
occlusion that contribute to the development of the severe complications of the disease such as 
cerebral malaria .  This phenomenon is associated with parasite proteins such as PfEMP1 that are 
expressed in the iRBC membrane that interact with receptors including CD36, thrombospondin, 
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and ICAM1 on the endothelial cells and leukocytes. 
 
Figure 3. Structures of carrageenans.  (a) The structure of κ-carrageenan shows 1 sulfate 
group. (b) ι-carrageenan shows 2 sulfate groups. (c) λ-carrageenan shows 3 sulfate groups.   
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Fig. 1 
 
 
 
 
 
 
 
 
  
18 
 
Fig. 2 
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Fig. 3 
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Abstract 
  This work shows the preparation and assessment of the sulfated derivative of the 
microbial polysaccharide gellan gum and derivatives of λ and κ-carrageenans for their in vitro 
inhibition of growth and invasion of red blood cells of P. falciparum 3D7 and Dd2.   Gellan gum 
and κ-carrageenan were sulfated using DMF-SO3, while λ –carrageenan was treated with HCl.  
The products were purified by dialysis and were added to  parasite cultures.   After 96 h, the 
cultures were assessed by flow cytometry for growth inhibition; and by counting the ring 
parasites after 20 h for invasion inhibition. Gellan sulfate showed strong inhibition of invasion 
and modest inhibition of growth for both P. falciparum 3D7 and Dd2 better than the native 
gellan gum.  The hydrolyzed λ-carrageenan and oversulfated κ-carrageenan were less inhibitory 
than their native forms.     In vitro cytotoxicity assays using the tetrazolium dye, MTT,  showed 
that the modified polysaccharides were not toxic to the 293T cells in vitro.  In vitro APTT 
anticoagulation assays showed that the synthesized gellan sulfate, in particular had low 
anticoagulant activity.   
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1. Introduction  
 
 There were an estimated 660,000 deaths from 220 million cases of malaria in 2010 [World 
Malaria Report, 2012]. This represents a decline in the mortality caused by malaria especially in 
the sub-Saharan endemic areas [Kweka, et al. 2013] and this success can be attributed to 
programs that include distribution of insecticide-treated nets, use of  indoor residual spraying, 
and expansion of malarial rapid diagnostic tests (RDTs).  But with the constant threat of the 
Plasmodium parasites and the Anopheles vectors developing resistance to established 
antimalarials and insecticides, the thrust to develop alternative antimalarial drugs, insecticides, 
and improved rapid diagnostic tests continues [Kweka, 2013].   
Plasmodium parasites,are obligate intracellular protozoa transmitted from a blood meal of 
the female Anopheles mosquito to humans.  In the erythrocytic stage of the disease, the 
Plasmodium merozoites invade red blood cells that results into the destruction of red blood cells 
and release of parasite and erythrocytic material into the circulation.  The host response to these 
events is manifested into the clinical symptoms of the disease which include intermittent fever, 
abdominal pain, anemia and overall weakness [Sherman, 1998]. 
Successful invasion of the erythrocyte is crucial for the survival of the malaria parasite.  
Upon egress, there is a short time window that the free malaria merozoites are exposed to the 
host’s immune system, which also provides an opportunity to target the parasites with vaccines 
or drugs [Yahata 2012].   
Erythrocyte invasion by the Plasmodium merozoite is a complex, multi-step process that 
involves interactions between the parasite and host cell proteins. The initial reversible attachment 
of the merozoite to the red blood cell may involve proteins on the merozoite surface, although 
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evidence to support this concept is needed. In the committed red cell binding, the merozoite 
reorients so that the apical complex makes contact with the erythrocyte surface. Here, the 
micronemes secrete invasion proteins, such as apical membrane antigen 1 (AMA1) and 
erythrocyte binding-like proteins (EBLs), and the rhoptries secrete reticulocyte binding-like 
proteins (RBLs) and rhoptry neck proteins (RONs). AMA1, a major candidate for a 
multicomponent vaccine against malaria [Schwartz 2012], interacts with the rhoptry neck 
proteins RON2, RON4, and RON5 to form a complex that is a critical component of the moving 
junction.  The EBLs and RBLs bind with receptors on the red blood cell and are implicated in 
host cell selection and alternative invasion pathways for the Plasmodium merozoite.  Merozoite 
entry into the red blood cell proceeds as the merozoite is propelled by an actin-myosin motor 
complex, with simultaneous shedding of the surface proteins to enable the parasite to adapt to its 
new intracellular environment [Cowman 2012, Gaur 2011, Harvey 2012]. 
Sulfated glycosaminoglycans (GAGs), such as heparin [Kulane 1992], dextran sulfate, 
fucoidan [Clark 1997, Xiao 1996], and carrageenans [Adams 2005] have been shown to inhibit 
merozoite entry into erythrocytes and prevent the cytoadherence of Plasmodium-infected red 
blood cells in vitro [Clark 1997, Xiao 1996].  
Heparin, in particular, has been shown to target several merozoite proteins [Zhang, 2013, 
Kobayashi, 2013] including invasion proteins such as merozoite surface protein 1 (MSP1) 
[Boyle, 2010] and erythrocyte binding antigen 140 (EBA-140) [Kobayashi 2010].  Thus, unlike 
other antimalarials, heparin can inhibit the invasion of red blood cells by the Plasmodium 
merozoites [Wilson, 2013].  MSP1 is a major candidate for a multi-component malaria vaccine 
[Schwartz 2012], and EBA-140, also known as BAEBL, is an erythrocyte binding ligand that 
interacts with the glycophorin C receptor on the erythrocyte surface [Lobo, 2003].  These 
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findings provide clues on how these invasion proteins interact with cell surface proteoglycans, 
such as heparan sulfate, and could help explain the mechanism by which sulfated 
polysaccharides inhibit parasite entry into red blood cells.  However, because heparin is a potent 
anticoagulant, it cannot be used to treat clinical malaria [WHO, 2010].  
 
Sulfated polysaccharides from marine sources are currently being exploited for their 
potential therapeutic applications. These include carrageenans from seaweeds, of which there are 
three major types, namely kappa (κ), lambda (λ), and iota (ι). These carrageenans differ in their 
levels of sulfation, which may also account for their different gelling properties. The 
carrageenans have been previously shown to inhibit the growth and invasion of red blood cells 
by Plasmodium falciparum 3D7 and Dd2 in vitro [Adams 2005]. In vivo, A/J mice pre-treated 
with calcium carrageenan prior to infection with P. berghei NK65A showed lower parasitemia 
compared with the untreated group, and a slight delay in the deaths of the infected mice [James 
1981]. In addition, Huber et al. [Huber 2002] showed that there was an increase in the 
permeability of the blood brain barrier in rats 72 h after subcutaneous administration of λ-
carrageenan. This side effect could enhance the development of cerebral malaria and is thus a 
major disadvantage of carrageenans for use in malaria. 
Studies on κ-carrageenan derivatives have shown improved potential of these derivatives 
against various pathogens.  Acetylated, sulfated, and phosphorylated κ-carrageenan derivatives 
were assessed for their antioxidant and antitumor properties [Yuan, 2005]. Other κ-carrageenan 
derivatives were found to be active against tumor cells [Yuan 2006, Yuan 2011], bacteria [Wang 
2011] and viruses, including influenza virus [Wang, 2011, Tang 2013], and human 
immunodeficiency virus [Vlieghe 2002]. I wanted to determine how modification of κ-
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carrageenan and λ-carrageenan could affect their action against malaria parasites and their safety 
as potential adjunct therapy for malaria. 
Gellan gum is a linear, anionic, high molecular weight, microbial polysaccharide produced 
by the bacterium Sphingomonas (Pseudomonas) elodea (ATCC 31461).  It is a thermoreversible 
gel, noted for its high gel strength and stability that make it useful as a drug vehicle, food 
additive, component of personal care products, and microbiological media. Its basic repeating 
unit is a tetrasaccharide, consisting of two glucose (Glc) residues, one glucuronic acid (GlcA), 
and one rhamnose (Rha) residue:  [→3)-β-D-Glcp-(1→4)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→4)-α-
L-Rhap-(1→]  [Ogaji 2012, Rinaudo 2000, Shah 2007, Goncalves 2009].  Tests on animals in 
which gellan gum was added to the diet or given by gavage, have shown that it is inert and safe 
for internal use [Shah 2007].   
Gellan gum has been modified to obtain sulfated derivatives (gellan sulfate) [Miyamoto 
2001] that were shown to have anticoagulant activities similar to heparin, except for one 
derivative, GS1, which had the lowest sulfonation ratio (5.0%),  and showed low anticoagulant 
activity [Miyamoto 2010].  At present, there are no published reports on the in vitro effect of 
gellan gum and gellan sulfate on malaria parasites.   
 
 
I wanted to assess synthetic compounds that can inhibit merozoite entry into red blood cells, 
similarly to heparin but with a better safety profile.  In the present study, I evaluated the 
microbial polysaccharide gellan gum and prepared its sulfated derivative, gellan sulfate,  and the 
carrageenan derivatives, hydrolyzed λ-carrageenan and oversulfated κ-carrageenan, for their 
inhibitory effects on the growth and invasion of erythrocytes by Plasmodium falciparum 3D7 
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and Dd2.  I also tested these compounds for their cytotoxicity to 293T cells in vitro.  The in vitro 
anticoagulant activity of the synthesized gellan sulfate was also assessed. 
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2. Materials and Methods 
2.1. Compounds and synthesis of gellan sulfate and carrageenan derivatives 
The polysaccharides used in this study were heparin (Sigma), λ-carrageenan (Sigma),         
κ-carrageenan (WAKO), and gellan gum (WAKO).  Hydrolyzed λ-carrageenan, oversulfated κ- 
carrageenan, and gellan sulfate were synthesized based on previously described methods with 
some modifications. 
Lambda carrageenan was hydrolyzed with hydrochloric acid at 70°C [Yuan 2005].  The 
mixture was then evaporated and lyophilized, and the resulting powder was dialyzed against 
distilled water. Final lyophilization yielded a light brown powder. For the oversulfated κ-
carrageenan [Yuan 2005] and gellan sulfate [Miyamoto 2001], sulfation was done by adding 
HClSO3 in DMF at 60°C after acid hydrolysis with HCl at 70°C.  After evaporation, 
lyophilization, and dialysis against distilled water, the resulting products were a brown powder 
of the oversulfated κ-carrageenan derivative and a white powder of gellan sulfate. 
Prior to mixing with the culture assays, the polysaccharides were first dissolved in distilled 
water to a concentration of 2 mg/ml, and then filtered through a 0.22-μm filter and then further 
diluted with the appropriate complete media. Polysaccharides that were insoluble at room 
temperature, namely; κ-carrageenan, λ-carrageenan, and gellan gum, were dissolved in distilled 
water at 80°C, while heparin, oversulfated κ- carrageenan, hydrolyzed λ-carrageenan, and gellan 
sulfate were dissolved at room temperature.  
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2.2. Analytical methods 
 13C NMR spectra were obtained from a JEOL 500 MHz spectrometer operating at 
500 MHz. The spectra for the oversulfated κ-carrageenan were recorded at 25 °C, while the 
spectra for the native gellan gum and the gellan sulfate were recorded at 90°C. Chemical shifts 
(δ in ppm) were expressed relative to the resonance of D2O (
1H NMR) (δ =4.8) and DMSO (13C 
NMR) (δ =39.5).  The samples for NMR analysis were dissolved in DMSO (oversulfated κ-
carrageenan=60 mg/ml; native gellan gum=5 mg/ml; gellan sulfate 20 mg/ml) and trace amount 
of D2O was added afterward.   
 The analysis of concentration of S was performed with Ion Chromatography System 
Dionex ICS-1100/1600 (Thermo Scientific Inc., MA USA).  The analysis of concentraion of C 
was performed with 2400 Series II CHNS/O System (Perkin Elmer Inc., MA, USA).  Degree of 
substitution (DS) was calculated using the formula given by Rochas et al [Rochas 1986]: [Eq. 1]   
DS = (S %/mol. wt. S) / (mol. wt. C x mol. no. of C) 
 
2.3. In vitro culture of Plasmodium falciparum parasites  
The chloroquine-sensitive line Plasmodium falciparum 3D7 and the chloroquine-resistant  
line, P. falciparum Dd2 parasites were maintained in continuous culture according to the 
methods described by Radfar et al [Radfar 2006].In this method, the parasites are grown in 
human A+ red blood cells and maintained in culture medium containing RPMI 1640, 25 mM 
HEPES, 100 μM hypoxanthine, 12.5 μg/ml gentamicin sulfate supplemented with 2.5% (w/v) 
Albumax II and 62.5 μg/ml of NaHCO3. Cultures were kept at 37°C, 5% CO2, and 5% O2 with 
daily medium changes; conditions were maintained at 1% hematocrit and 1% parasitemia. 
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2.4. Cell culture 
Human embryonic kidney derived 293T cells were grown at 37°C, 5% CO2, and 5% O2  in 
culture medium containing DMEM, L-glutamine, penicillin-streptomycin, and 62.5 μg/ml 
NaHCO3, supplemented with 10% fetal calf serum and passaged every two days at 70%–80% 
confluency. 
 
2.5. Growth Inhibition Assay 
Growth inhibition assays (GIAs) were performed as previously described [Persson, 2006]. 
Predominantly ring stage cultures were first synchronized by sorbitol treatment.  GIAs were 
carried out at the next day, when the cultures were mostly in the late trophozoite stage.  Infected 
red blood cells were mixed with fresh Type A+ RBCs to make cultures with 0.30% parasitemia 
and 1% hematocrit. A 25-μl aliquot of culture was then transferred into 96-well plates and 2.5 μl 
of the inhibitors was added to each well such that the final concentrations were 9, 4.5, 2.25, and 
0.9 μg/ml. Three independent experiments were performed and all were done in triplicate and 
parallel cultures were also maintained.  The cultures were incubated at 37°C, with 5% CO2, and 
5% O2.  At 48 h post-incubation, 5 μl of complete medium was added to each culture.  Flow 
cytometry was used to determine the parasitemia after 90–96 h when the parasites were mostly in 
the trophozoite-schizont stages. 
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2.6. Flow cytometric analysis 
Flow cytometric analysis was carried out to determine the parasitemia of the cultures 
[Persson, 2006]. Cultures were mixed with 10 μg/ml ethidium bromide in PBS and were left at 
room temperature for 1 h in the dark.  The cell pellets were then resuspended in 500 μl of PBS 
and transferred into flow cytometry tubes. Flow cytometric analysis was carried out on a 
FACSCalibur (BD Biosciences) and the data were analyzed with WinMDi ver. 2.9. 
 
2.7. Invasion Inhibition Assay 
For the invasion inhibition assays [Bates 2010, Spadafora, 2011], cultures were purified by 
using MACS® (Miltenyl Biotec, Japan) magnetic beads separation column to obtain trophozoite 
and schizont stage parasites.  Purified schizonts were mixed with complete medium to obtain 
hematocrit of 1%, and fresh A+ red blood cells were added for a total parasitemia of 5% with 
ring stage parasitemia of almost 0%.  Cultures (100 μl) were transferred into 96-well round 
bottom plates and the inhibitors heparin, gellan gum, and gellan sulfate were added to a final 
concentration of 100 μg/ml.  As a negative control, distilled water was added to cultures to a 
final concentration of 5% and was incubated for 20 h at 37°C, with 5% CO2 and 5% O2. These 
assays were done in triplicate and at least three independent similar experiments were performed. 
 
2.8. Assessment of invasion inhibition  
Culture supernatants were aspirated and the cell pellets were smeared and stained with 
Giemsa staining to determine ring stage parasitemia.  Means and standard deviations of ring 
stage parasitemia were obtained and the percent inhibition was computed using the following 
formula:  [Eq.2] {(Mean % Ring stage parasitemia of DW-treated culture – Mean % Ring stage 
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parasitemia of inhibitor-treated culture) ÷ Mean % Ring stage parasitemia of DW-treated 
cultures} x 100% ; DW = distilled water. 
 
2.9. Cytotoxicity assays  
MTT assays were performed using 293T cells.  The cells were seeded in 96-well flat-bottom 
wells with a culture volume of 100 μl at a 2:1000 dilution and incubated at 37°C, 5% CO2, and 
5% O2. After 24 h, when the cells reached about 50% confluency, the old media were aspirated 
and replaced with 100 μl of complete medium containing inhibitors at concentrations of 500, 
250, 100, 50, 25, and 10 μg/ml. These inhibitors were mixed with the cells and incubated at 
37°C, 5% CO2, and 5% O2 for 48 h.  MTT solution (10μl of 5mg/ml) was added to the culture, 
which was kept in the dark at room temperature overnight.  The following morning, the old 
media were aspirated and 100 μl of DMSO was added as an MTT solvent.  The cells were then 
assessed by measuring the absorbance at 595nm and the % cell viability was computed as 
follows [Edmondson, et al.1988]: [Eq. 3]   % cell viability = (absorbance595nm of treated group ÷ 
absorbance595nm of control group) x 100 %. 
 
2.10. In vitro Anticoagulant Activated Partial Thromboplastin Time (APTT) Assay  
 Blood was collected from the hearts of normal adult female C57BL/6 mice under 
terminal ether anesthesia.  The bloods collected were mixed immediately with 3.2% trisodium 
citrate at 9:1 blood: anticoagulant ratio.  The plasma were obtained by spinning the blood in a 
bench top centrifuge for 15 minutes and pooled.  Ten μl of heparin, gellan gum and gellan sulfate 
each diluted in PBS were mixed with the 100 μl  plasma for a final concentration of 10 μg/ml 
and then incubated at 37°C for 1 min [Shi, et al. 2007].  APTT assay was performed using 
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Drihemato® APTT Test Reagent Card (A&T Corporation, Japan) according to manufacturer’s 
instructions.  Fifty μl of  plasma was added to a drop of Drihemato® PT-APTT Specimen 
Diluent B and mixed thoroughly.  Twenty-five μl of the plasma and diluent mixture was then 
placed on the Drihemato® APTT Test Reagent Card and the coagulation time was read in a 
Drihemato® system Coag2V machine.  The coagulation times were recorded in seconds (s). 
 
2.11. Animals 
 Adult female C57BL/6 mice purchased from CLEA Japan (Tokyo, Japan) were 
maintained in  controlled light and dark conditions and were given commercial feed and water ad 
libitum.   Animal experiments were conducted in accordance with the Principles for the Care and 
Use of Research Animals of Obihiro University of Agriculture and Veterinary Medicine.  The 
protocol for the animal experiments was approved by the Committee on the Animal Experiments 
of the Obihiro University of Agriculture and Veterinary Medicine (Permit No. 25-153, 2013). 
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3. Results   
3.1. Synthesis of gellan gum, λ- and κ-carrageenan derivatives 
-Carrageenan and gellan gum were sulfated by SO3-pyridine complex.  The κ-carrageenan 
and gellan sulfates, and the hydrolyzed λ-carrageenan were more readily soluble in distilled 
water at room temperature compared with their native counterparts.  The modified 
polysaccharides also did not form gels in solution. 
 Degree of substitution (DS) of the sulfonyl group and sulfation rate (%) were determined 
by elemental analyses, as listed in Table 1.  DSs for -carrageenan and gellan were defined as 
molar number of sulfonyl group per di-saccharide and tetra-saccharide units, respectively 
 NMR analyses were employed to confirm sulfation of κ-carrageenan and gellan.  13C-
NMR spectra before and after sulfation are given in Figures 1 and 2.  The peaks of native -
carrageenan and gellan were assigned according to the assignments reported in the previous 
articles [Jay 1998, van de Velde 2002, de Araujo 2013].   The major peaks of sulfated -
carrageenan with DS of 3.0 were also assigned according to the assignments for sulfated -
carrageenan with DS of 3.1 reported in the previous studies [de Araujo 2013, Thahn 2001]. The 
overlapped peaks of ring-carbons of gellan sulfate with DS of 3.7 were hardly assigned due to 
their complex appearance caused by sulfonyl substituents and remaining hydroxyl groups.   In 
the case of -carrageenan, shift of the peaks of C6 (G) from 61.4 to 66.5 ppm, C2 (G) from 69.7 
to 75.4 ppm and C2 (A) from 70.0 to 72.7 ppm are indicative for successful sulfation at these 
positions.   Complete disappearance of the peak assigned C6 (G) is indicating that C6 (G) 
position is completely substituted.  Other peaks are likely assigned to ring carbons of un-
substituted sugar units.  In the case of gellan, the peaks assigned to C6 (13G) at 61.7 ppm, C6 
(14G) at 62.2 ppm, C2 (R) at 71.6 ppm, and C3 (R) at 71.7 ppm, completely disappeared, 
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indicating preferential sulfation at these positions.   
 
 
3.2. Growth Inhibition Assay 
The native λ- and carrageenans inhibited the growth of Plasmodium falciparum 3D7 
(Figure 3A) and Dd2 (Figure 3B) in vitro consistent with the observations of Adams et al 
[Adams 2005]  in a concentration-dependent manner. Both the hydrolyzed λ-carrageenan and the 
oversulfated κ-carrageenan derivatives showed poor inhibition of P. falciparum 3D7 and Dd2 
growth in vitro. Gellan sulfate (9 μg/ml) inhibited growth of Plasmodium falciparum 3D7 
(55.33%) and Dd2 (85.83%) in vitro (Figure 3A and 3B).  In contrast, native gellan gum 
exhibited low inhibition (23.04%, 3D7; and, 39.22%, Dd2) at the same concentration.  From 
here, I chose to further assess gellan sulfate for its ability to inhibit invasion. 
 
3.3. Invasion Inhibition Assay 
At 100 μg/ml, gellan sulfate showed strong inhibition of invasion of Plasmodium falciparum 
3D7 (96.15%) (Figure 4A and 4C) and Dd2 (98.17%) (Figure 4B and 4D) in vitro that was 
comparable to that of heparin (98.79% for 3D7 and 96.16% for Dd2).  Native gellan gum, on the 
other hand, showed little inhibition of invasion for both Plasmodium falciparum 3D7 and Dd2. 
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3.4. Cytotoxicity Assays 
Unlike the native gellan gum, gellan sulfate does not gel in solution.  With this change in 
property I wanted to determine the safety of the gellan sulfate for future in vivo studies.  Hence, I 
performed MTT cytotoxicity assays on 293T cells using the original selection of inhibitors for 
comparison (Figure 5A). Heparin and native gellan gum treatment caused a marked decrease in 
cell viability at concentrations of 250 and 500 μg/ml (54.68% and 70.18% for heparin; 79.86% 
and 57.74% for gellan gum).  By contrast, gellan sulfate, as well as the native λ- and κ- 
carrageenans and their respective derivatives, showed relatively low cytotoxicity at 500 μg/ml 
(86.44%, 81.52%, 89.33%, 101.88% and 94.30%, respectively).   
 
3.5. In vitro anticoagulant activity of gellan sulfate 
 The in vitro anticoagulant activity of the gellan sulfate was assessed by activated partial 
thromboplastin time (APTT) anticoagulant assays using healthy mouse plasma [Shih 2007].   In 
separate experiments, the normal APTT value for plasma from a healthy animal ranged from 
21.8 s to 27.1 s, with mean value of 23.4 s.  As shown in Figure 5B, the APTT for plasma with 
heparin at 10 μg/ml increased dramatically (mean = 181.0 s), whereas for plasma with 10 μg/ml 
gellan sulfate, the mean APTT was 28.7 s.  The plasma with 10μg/ml native gellan gum had a 
mean APTT time of 22.5 s. This shows that the  synthesized gellan sulfate has  low anticoagulant 
activity. 
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4. Discussion 
Polysaccharides from marine sources are currently gaining popularity for their potential 
medical and therapeutic applications.  Seaweed-derived polysaccharides like carrageenans 
[Adams 2005] and fucoidan [Chen 2009] have been shown to inhibit the growth and invasion of 
P. falciparum in vitro.  However, in in vivo studies, although a decrease in parasitemia may have 
been observed, there was no significant improvement in the recovery of mice from the illness 
[James 1981, Chen 2009]. In addition, λ-carrageenan was found to increase the permeability of 
the blood-brain barrier of rats when injected subcutaneously [Huber 2002].  This may aggravate 
the disease by adding to the development of cerebral malaria. 
Although the exact mechanism of inhibition by these sulfated polysaccharides is yet to be 
defined, it may be related to the interactions of the malarial invasion proteins with the sulfated 
proteoglycans like heparan sulfate and chondroitin sulfate that are present on the surface of most 
cell types including the erythrocyte. These interactions have been demonstrated by Boyle et al. 
[Boyle 2010] and our group [Kobayashi 2013], where heparin was shown to interact with the 
invasion proteins MSP1 and EBA-140, respectively. 
Naturally-occuring polysaccharides have been modified by sulfation and assessed for their 
biological activities such as anticoagulant, antibacterial and antiviral activities.  Galactomannans 
from seed extracts that were modified by sulfation have been shown to have activities against 
yellow fever virus and dengue 1 virus in vitro and in vivo [Ono, et al, 2003], and against HIV in 
vitro [Muschin 2012].  Sulfated konjac glucomannans, have also been shown to act against HIV 
[Bo 2013].  
Modification of  κ-carrageenan has  been shown to improve its action  against a variety of 
pathogens. Low molecular weight κ-carrageenan (3 kDa) and κ-carrageenan oligosaccharides 
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(KOS), as well as their sulfated derivatives have been shown to have anti-influenza virus effects 
both in vitro and in vivo [Wang 2011, Tang 2013]. KOS was also reported to have enhanced 
immunostimulatory and antitumor activities [Yuan 2005, Yuan 2006]. In addition, -carrageenan 
that was covalently bound to 3’-azido-3’-deoxythymidine AZT, was found to be active against 
human immunodeficiency virus in vitro.   
Gellan sulfate has been prepared and intended for various medical applications such as an 
artificial ligand to remove the extra domain A containing fibronectin (EDA(+)FN) from plasma 
of rheumatoid arthritis (RA) patients [Miyamoto 2001], and as a novel anticoagulant [Miyamoto 
2010].   
 
Thus, I synthesized oversulfated κ-carrageenan and gellan sulfate and I assessed the 
activities of these derivatives against malaria parasites in vitro.   Elemental analysis showed that 
the synthesized oversulfated κ-carrageenan and gellan sulfate have sulfate content of 13.6% and 
9.57%, respectively (Table 1.).   The degree of substitution values (DS) were calculated as 3.0 
for -carrageenan and 3.7 for gellan [Rochas 1986, Melo 2002].  Note that maximum DSs for 
carrageenan and gellan are 4 and 10, respectively.  Sulfation rates (%) of -carrageenan and 
gellan sulfates relative to maximum DS were calculated as 75 % and 37 %.     
The synthesized oversulfated κ-carrageenan and hydrolyzed λ-carrageenan did not show any 
activity against Plasmodium parasites which is different from the previously reported modified 
carrageenans. These differences could be attributed to the different modes of invasion and 
replication of the viruses within host cells compared with that of parasites.  
The results show that the synthesized gellan sulfate effectively inhibited both the growth and 
invasion of the P. falciparum merozoites in vitro unlike the native gellan gum yet similar to 
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heparin.  However, unlike heparin, gellan sulfate  makes a suitable  selective artificial ligand for 
EDA(+)FN from plasma of rheumatoid arthritis (RA) patients because it does not bind to 
proteins such as plasma fibronectin and antithrombin III [Miyamoto 2001].  Gellan sulfates with 
17.5% sulfation or greater were also shown to be potent anticoagulants like heparin [Miyamoto 
2010]. However, based on the cytotoxicity and anticoagulant assays the synthesized gellan gum 
with 37% sulfation was shown to have low anticoagulant activity.  The reason for this difference, 
though, is unclear at this point. 
  
39 
 
Figure legends 
Figure 1. 
13
C NMR spectra of (a) unsubstituted κ-carrageenan and (b) oversulfated κ-
carrageenan (R = SO3- or H).  G-S and A-S represent sulfated G and A units. Shift of the 
peaks of C6 (G) from 61.4 to 66.5 ppm, C2 (G) from 69.7 to 75.4 ppm and C2 (A) from 70.0 to 
72.7 ppm are indicative for successful sulfation at these positions.   Complete disappearance of 
the peak assigned C6 (G) is indicating that C6 (G) position is completely substituted.   
 
Figure 2. 
13
C-NMR spectra of (a) gellan (R = H) and (b) sulfated gellan (R = SO3- or H).  
The complete disappearance of peaks assigned to C6 (13G) at 61.7 ppm, C6 (14G) at 62.2 ppm, 
C2 (R) at 71.6 ppm, and C3 (R) at 71.7 ppm, indicate preferential sulfation at these positions.   
 
Figure 3. In vitro growth inhibition assay of P. falciparum 3D7 (A) and Dd2 (B).   Late stage 
P. falciparum 3D7 and Dd2 trophozoites (parasitemia 0.3 %, hematocrit 1%) were cultured in 
the presence of the following inhibitors: heparin (HEP), gellan gum (GG), gellan sulfate  (SGG), 
λ-carrageenan (LA), hydrolyzed λ-carrageenan (HLA), κ-carrageenan (KP), and oversulfated κ-
carrageenan (OSK) in 96-well round-bottom plates for 96 h.  Final parasitemia was determined 
by use of flow cytometry. Percent inhibition is shown (y-axis) against increasing concentrations 
(x-axis) of each inhibitor. At 9μg/ml, SGG inhibited the growth of the P. falciparum 3D7 by 
56% and Dd2 by 80%. At the same concentration, GG, HLA, and OSK inhibited both P. 
falciparum clones by 20% or less.  In three independent assays, SGG consistently inhibited the 
growth of P. falciparum 3D7 by less than 60% and Dd2 by 70-80% (data not shown). 
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Figure 4.  In vitro invasion inhibition assay of P. falciparum 3D7 and Dd2.  MACS-purified 
P. falciparum 3D7 and Dd2 schizonts were cultured in 96-well round-bottom plates (ring stage 
parasitemia = 0%, hematocrit = 1%) for 20 h in the presence of 100 μg/ml heparin (HEP 100), 
gellan gum (GG 100), gellan sulfate (SGG 100), or distilled water (DW). Percent inhibition of 
invasion by P. falciparum 3D7 and Dd2 is shown in (A) and (C), respectively. Ring stage 
parasitemia for each treatment, as determined by examining Giemsa-stained smears, is shown in 
(B) for P. falciparum 3D7 and in (D) for P. falciparum Dd2.  Untreated groups are labeled as 
(Untreated).  All assays were done in triplicate wells and three independent experiments were 
performed. 
 
Figure 5.  Cytotoxicity and Activated Partial Thromboplastin Time (APTT) assays (a) 
Cytotoxicity assays using 293T cells.  Cultures of 293T cells (100 μl) were seeded into 96-well 
flat-bottom plates and incubated at 37°C.  At about 50% confluence, the old media were replaced 
with fresh media containing the inhibitors heparin (HEP), gellan gum (GG), gellan sulfate 
(SGG), λ-carrageenan (LA), hydrolyzed λ-carrageenan (HLA), κ-carrageenan (KP), or 
oversulfated κ-carrageenan (OSK) and the cells  were incubated at 37°C for 48 h.  MTT (10 μl) 
was then added to the cultures, which were kept in the dark overnight (about 12 h) at room 
temperature.  Absorbance was read at 595 nm and the % cell viability was computed as:  % cell 
viability = (absorbance595nm of treated group ÷ absorbance595nm of control group) x 100%.  Means 
and standard deviations from the means were computed from triplicates assay in three 
independent experiments. (b)  Activated Partial Thromboplastin Time (APTT) Assays.   
Pooled plasma from adult C57BL/6 mice was used for the APTT anticoagulant assays.  Ten μl of 
heparin, gellan gum and gellan sulfate each diluted  in PBS were mixed with the 100 μl  plasma 
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for a final concentration of 10μg/ml and then incubated at 37°C for 1 minute.  APTT assay was 
performed using Drihemato® APTT Test Reagent Card (A&T Corporation, Japan) according to 
manufacturer’s instructions.  Fifty μl of plasma was added to a drop of Drihemato® PT-APTT 
Specimen Diluent B and mixed thoroughly.  Twenty-five μl of the plasma and diluent mixture 
was placed on the Drihemato® APTT Test Reagent Card and the coagulation time (in seconds) 
was read in a Drihemato® system Coag2V machine.  Two independent assays were performed in 
triplicates and means and standard deviations were calculated.   
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CHAPTER 1 
Table 1.  Characteristics of sulfated κ-carrageenan and gellan gum 
 
 
 
 
 
 
 
 
 
 
Percent carbon (C), 
hydrogen (H), and 
sulfur (S) as 
determined by elemental analyses.  DS was calculated according to the equation given by Rochas 
et al [Rochas 1986] as follows.  DS=(S%/atomic mass of S)/(C%/atomic mass of C × number of 
carbons for one unit). Sulfation rate (%) was calculated by taking ratio of DS of sulfonyl group 
to maximum DS of 4 for -carrageenan and 10 for gellan, respectively 
 
 
 
 
 
 
  
Table 1. Characteristics of sulfated -carrageenan and gellan gum 
Sulfated derivatives 
Elemental analysis (%) 
 
DS
a
 
Sulfation rate 
(%)
a
 
 
C H S 
  
Carrageenan 20.3 4.09 13.6 
 
3.0 75 
 
Gellan 23.3 4.38 9.57 
 
3.7 37 
 
a
Relative to maximun DS: 4.0 (-carrageenan), 10.0 (gellan) 
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Fig. 3 
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Fig. 5 
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CHAPTER 2 
Assessment of the in vivo inhibition of growth of the rodent malaria 
parasites, Plasmodium yoelii 17XL in BALB/c mice and Plasmodium 
berghei ANKA in C57BL/6 mice using gellan sulfate 
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Abstract 
Our group synthesized gellan sulfate, a novel anticoagulant derivative of the microbial 
polysaccharide, gellan gum. Gellan sulfate was shown to inhibit the growth and invasion of 
erythrocytes by the Plasmodium falciparum parasites in in vitro assays.   Also, the synthesized 
gellan sulfate was found to have low cytotoxicity and anticoagulant activities in vitro.  Here, the 
potential of gellan gum as a safer alternative to heparin as adjunct therapy to malaria was further 
assessed in in vivo experiments using the lethal rodent malaria parasites, Plasmodium yoelii 
17XL in BALB/c mice and P. berghei ANKA in C57BL/6 mice following the four day 
suppressive test.  The native gellan gum was tested as well.  Gellan sulfate, as well as the native 
gellan gum, showed low inhibition of the growth rate of both Plasmodium yoelii 17XL in 
BALB/c mice and P. berghei ANKA in C57BL/6 mice.  However, there was a delay in the 
mortality of the C57BL/6 mice infected with P. berghei ANKA that were treated with both 
gellan sulfate and the native gellan gum. 
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1. Introduction 
Current antimalarial drugs act on intra-erythrocytic Plasmodium parasites [Wilson 2013].  
At this stage, the disease is already manifested with signs like fever and malaise, and diagnosis 
can be done with parasites demonstrated in blood smears.   
Quinine, one of the oldest antimalarial agents, was extracted from the bark of the Cinchona 
trees which are native to the Andes in South America.  Quinine and quinine derivatives have 
been synthesized in the laboratory, making it readily available commercially. Its mode of action 
involves in binding heme in the Plasmodium lysosome, inhibiting heme crystallization.  
[Sullivan, 2012]. 
Artemisinins are currently the preferred treatment for severe malaria.  Artemisinin-based 
combination therapies (ACTs) are recommended for uncomplicated malaria. Artemisinin was 
derived from the Artemisia plant leaf extracts in China.  Similar to quinine, artemisinin 
derivatives had been synthesized that makes them readily available commercially [Karunajeewa 
2012]. The mechanism of action of artemisinins also involves interfering with the hemoglobin 
uptake and digestion of the parasite [Klonis 2013].   
The development of resistance against antimalarials continues to hinder the efforts to 
eradicate malaria in the world.  Recently, the emergence of resistance against artemisinins on the 
Thai/Cambodia border was reported [Samarasekera 2009].   It is yet unclear whether these 
resistant parasites have spread to other areas but such development threatens the progress of the 
control and elimination of malaria.  Hence, the continuing trials to develop preventive vaccines 
and novel drugs are needed. 
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Heparin, a highly sulfated polysaccharide, which binds to several proteins of the malaria 
parasites, inhibits the entry of the parasites into the red blood cells in vitro [Wilson 2013].  In 
addition, heparin can also inhibit cytoadherence and sequestration of infected red blood cells to 
the vascular endothelium [Xiao 1996] and its low molecular weight derivatives can also prevent 
rosetting in vitro [Skidmore 2008].  However, heparin is not safe for use in clinical malaria 
because of its anticoagulant properties that can cause intracranial bleeding to the infected 
individual [WHO 2010].  Other sulfated polysaccharides like dextran sulfate [Xiao 1996], 
carrageenans [Adams 2005], and fucoidan [Chen 2009] have been found to inhibit the parasite 
entry into red blood cell in vitro.  But the effectiveness in vivo of these polysaccharides is still 
inconclusive [James and Alger 1981; Chen 2009; Beuria 1991]. 
Heparin derivatives are also gaining interest as a safer alternative to heparin that can be 
used in clinical malaria. One example of which is the depolymerized heparin glycans that lack 
anticoagulant activity and were shown to release sequestered P. falciparum iRBCs in Macaca 
fascicularis [Vogt, et al. 2006]. Blood-stage antimalaria vaccines designed to prevent parasite 
entry into the red blood cells are still currently under testing. In this light, I wanted to assess the 
in vivo effect of the gellan sulfate, synthesized in our laboratory, which was earlier found to not 
only effectively inhibit parasite entry and growth in vitro, but  also to be non-cytotoxic and  
weakly anticoagulant  in in vitro tests. 
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2. Materials and Methods 
2.1. Parasites 
Frozen stock of Plasmodium yoelii 17XL parasites was provided by Prof. Osamu Kaneko 
(Nagasaki University) and was passaged in BALB/c mice.  Frozen stock of P. berghei ANKA 
parasites was provided by Dr. Alaa Terkawi in National Research Center for Protozoan Diseases 
(NRCPD), Obihiro University of Agriculture and Veterinary Medicine, and was passaged in 
C57BL/6 mice.   
 
2.2. Animals 
Female BALB/c and C57BL/6 mice, five weeks of age were purchased from CLEA Japan 
(Tokyo, Japan).  The animals were maintained in the animal care facility in NRCPD, Obihiro 
University of Agriculture and Veterinary Medicine under controlled conditions and were given 
commercial feeds and water ad libitum.  The protocol for the animal experiments was approved 
by the Committee on the Animal Experiments of the Obihiro University of Agriculture and 
Veterinary Medicine (Permit No. 25-153, 2013). 
 
2.3. Compounds 
Artesunate (SIGMA) was dissolved in 1% sodium bicarbonate in PBS (2 mg/ml) and filter-
sterilized.  Gellan gum (WAKO) and gellan sulfate were both dissolved in PBS (2 mg/ml) and 
filter-sterilized.   
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2.4. Infection and Treatment 
Donor mice were infected intraperitoneally with 106 parasitized red blood cells from 
cryopreserved stock.  P. yoelii 17XL infected blood from the BALB/c donor mice were collected 
when parasitemia reached 15%.  P. berghei ANKA infected blood from the C57BL/6 donor mice 
were collected at 6% parasitemia before presumed onset of cerebral malaria.  
Experimental mice were infected intraperitoneally with 106 parasitized red blood cells and 
were sorted into four treatment groups:  control untreated, artesunate-treated, gellan gum-treated, 
and gellan sulfate-treated groups.  For ethical reasons, control animals were not given any kind 
of treatment.   
Treatment and monitoring protocol followed the four-day suppressive test.  Artesunate was 
given intraperitoneally at a dose of 20 mg/kg.  Gellan gum and gellan sulfate were given 
intraperitoneally at various doses: for the BALB/c mice, 25 mg/kg, and; for the C57BL/6 mice, 
20 mg/kg and 50 mg/kg.  The day of infection was designated as day 0, and the first treatment 
was given 2 hours later.  Succeeding treatments were given every 24 hours until day 3 post-
infection, for a total of four treatments.  Parasitemia monitoring was started at day 4 until day 10 
post-infection with Giemsa stained thin blood smears.  For parasitemia counting, 10 oil 
immersion fields were counted with 200-300 cells, except for parasitemias approaching zero, in 
which cases, 100 fields were examined.  Weights and demeanor were monitored to check for 
signs of toxicity from the treatments.   Deaths were promptly recorded. 
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3.  Results  
Here the antimalarial effects of the synthesized gellan sulfate were assessed using mouse 
models infected with the lethal parasites P. yoelii 17XL and P. berghei ANKA. In all in vivo 
experiments, the parasitemia of the gellan sulfate and the gellan gum treated groups after the 
four-day suppression of growth were similar and sometimes higher than in the control groups.    
In the BALB/c mice infected with P. yoelii 17XL (Figure 1A), hyperparasitemia was 
observed in the control (37.88%), gellan gum (28.82%) and gellan sulfate (26.13%) treated mice 
in as early as day 4 post-infection.  There was also an observed decline in parasitemia from day 6 
post-infection.  However, this may be attributed to the ensuing anemia rather than the actual 
effect of the treatments.   
BALB/c mice suffering from high parasitemia died at days 5 and 6 p.i (Figure 1B), while 
some mice persisted until day 25 p.i.  All artesunate-treated mice survived beyond day 30 p.i. 
and eventually recovered from the infection. 
Similarly, in C57BL/6 mice infected with P. berghei ANKA parasitemias of the control 
and the gellan gum (20 mg/kg) and gellan sulfate (20 mg/kg) treated groups at day 4 p.i. were 
almost similar (Figure 2A).  Also, the increase in parasitemia for these groups was almost the 
same.  However, all mice (n=3) from the control group died at days 5 and 6 p.i. (Figure 2B), 
while one mortality from both the gellan gum and gellan sulfate treated groups were noted at day 
7 p.i.  Artesunate-treated mice eventually succumbed to the infection by day 26-28 p.i. while the 
last gellan gum and gellan sulfate treated mice died at day 35 and 38 p.i, respectively.   
When the doses of gellan gum and gellan sulfate were increased to 50 mg/kg, a similar 
profile of parasitemia was observed in C57BL/6 mice infected with P. berghei ANKA (Figure 
3A).  In this experiment, mice receiving this dose of both gellan gum and gellan sulfate showed 
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weight loss and ruffled hair.  These may be interpreted as signs of toxicity, and indicate that this 
dose is not safe for the mice.  Majority of the mice persisted beyond day 25 p.i (Figure 3B), but 
all mice had died of  the infection by day 31 p.i. 
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4. Discussion 
 In spite of showing good inhibition of growth and invasion of P. falciparum 3D7 and 
Dd2 in vitro, gellan sulfate was found to be less effective in inhibiting the growth of the rodent 
malaria parasites P. yoelii 17XL and P. berghei ANKA in vivo. Several factors can be considered 
to affect the effectiveness of drugs in the animal body.  The animal’s immune response to the 
disease itself is a major determinant of the course of the disease and response to treatment.  The 
method of administration and the delivery system affect the absorption and metabolism of drugs. 
 Gellan gum is currently being utilized as drug delivery system, and is reportedly safe 
when given orally and parenterally.  When mixed in the diet of Swiss Crl mice for 96-98 weeks, 
gellan gum showed no effects on the body weight or food consumption of the animals, nor were 
there any observed neoplastic or non-neoplastic changes associated with feeding gellan gum 
[Shah 2007].  Gellan gum 1% (w/v) discs showed no significant lesions when implanted in the 
dorsal part of the BALB/c mice for 21 days [Oliveira 2010].  However, there are no reports on 
the nutritive or therapeutic benefits of gellan gum.   
 Gellan sulfate, the sulfated derivative of gellan gum, was originally developed as a novel 
anticoagulant [Miyamoto 2010].   In this study, when gellan gum and gellan sulfate were given at 
the dose of 50 mg/kg, some signs of possible toxicity were noted, such as weight loss, stunted 
growth and ruffled hair.  Although some of these changes can also be attributed to the ongoing 
disease itself, when given at a dose of 20-25 mg/kg, the gellan gum and gellan sulfate treated 
mice appeared normal until the onset of the clinical disease.  Based on these observations, I can 
say that the dose of 20-25 mg/kg, gellan gum and gellan sulfate are safe to be given 
intraperitoneally.   
The survivals of the infected mice varied from 6 days to more than 30 days for both 
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Plasmodium yoelii 17XL and Plasmodium berghei ANKA infections.   
Deaths in the Plasmodium berghei ANKA infected groups treated with artesunate may be 
attributed to the limited time of treatment.  Oral artesunate given at 10mg/kg/day for 7 days has 
been shown to prevent parasitemia but with likelihood of recrudescence of parasitemia and 
development of cerebral malaria [Gumede et al. 2003].  A 14-day treatment course of oral 
artesunate and at 100mg/kg/day completely prevented development of parasitemia and cerebral 
malaria [Gumede et al. 2003].   For the purposes of comparison, to show the suppression of 
growth of the parasites, I believe it was shown here that artesunate inhibited growth and 
proliferation of the parasites during the early stages of the disease under drug pressure.  The 
termination of treatment then allowed the parasites to proliferate and the disease was allowed to 
run its course. 
An interesting observation was that some of the P. berghei ANKA infected C57BL/6 mice 
that were treated with gellan gum and gellan sulfate showed signs of cerebral malaria such as 
hind limb paralysis and head tilting at around day 7 p.i. Afterwards, these mice apparently 
recovered from CM and persisted for the next 3 weeks.  The exact mechanisms of how gellan 
gum and gellan sulfate prolonged the survival of the infected mice, however, was not examined 
in this thesis.  It may be hypothesized that the gellan sulfate has an inhibitory effect on the 
cytoadhesion and sequestration of infected red blood cells that is similar to that of heparin and its 
derivatives.  How this applies to the effect of the native gellan gum, which is not sulfated, still 
needs further investigation. 
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Figure legends: 
 
Figure 1.  (a) Parasitemia and (b) survival monitoring on BALB/c mice infected with P. 
yoelii 17XL.  BALB/c mice were infected intraperitoneally with 106 P. yoelii 17XL infected red 
blood cells.  Groups of 3 mice were given artesunate (20 mg/kg), gellan gum (25 mg/kg) and 
gellan sulfate (25 mg/kg) intraperitoneally, following the 4-day suppressive test protocol, with 
treatment 1 given 2 h post-infection and every 24 h thereafter until day 3 p.i.  (a) Parasitemia was 
measured by Giemsa stained thin blood smears from day 4-10 p.i.  (b) Mortality and survival of 
the infected mice were noted.  (dpi – day post-infection), (†) indicate mouse that died. 
 
 
Figure 2.  (a) Parasitemia and (b) survival monitoring on C57BL/6 mice infected with P. 
berghei ANKA, using 20mg/kg gellan gum and gellan sulfate.  C57BL/6 mice were infected 
intraperitoneally with 106 P. berghei ANKA infected red blood cells.  Groups of 3 mice were 
given artesunate (20 mg/kg), gellan gum (20 mg/kg). Gellan sulfate (20 mg/kg) intraperitoneally, 
following the 4-day suppressive test protocol, with treatment 1 given 2 h post-infection and 
every 24 h thereafter until day 3 p.i.  (a) Parasitemia was measured by Giemsa stained thin blood 
smears from day 4-10 p.i.  (b) Mortality and survival of the infected mice were noted.  (dpi – day 
post-infection),  (†) indicate mouse that died 
 
Figure 3.  (a) Parasitemia and (b) survival monitoring on C57BL/6 mice infected with P. 
berghei ANKA, using 50 mg/kg gellan gum and gellan sulfate. C57BL/6 mice were infected 
intraperitoneally with 106 P. berghei ANKA infected red blood cells.  Groups of 3 mice were 
given artesunate (20 mg/kg), gellan gum (50 mg/kg), and gellan sulfate (50 mg/kg) 
intraperitoneally, following the 4-day suppressive test protocol, with treatment 1 given 2 h post-
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infection and every 24 h thereafter until day 3 p.i.  (a) Parasitemia was measured by Giemsa 
stained thin blood smears from day 4-10 p.i. (b) Mortality and survival of the infected mice were  
noted.  (dpi – day post-infection),  (†) indicate mouse that died. 
 
 
 
  
60 
 
CHAPTER 2 
Fig. 1 
  
61 
 
CHAPTER 2 
Fig. 2 
 
 
 
 
 
 
 
 
 
 
 
  
62 
 
CHAPTER 2 
 
Fig. 3 
 
  
63 
 
 
 
 
 
 
 
 
 
GENERAL CONCLUSION 
  
64 
 
     
In chapter 1, I described the detail of the synthesis of modified polysaccharides, namely:  
oversulfated κ- and hydrolyzed λ-carrageenans, and gellan sulfate, the sulfated derivative of the 
microbial polysaccharide gellan gum.  Nuclear magnetic resonance spectroscopy and elemental 
analysis showed successful sulfation of κ-carrageenan and gellan gum.   These derivatives were 
then evaluated for their activities against the human malaria parasites, P. falciparum, in vitro.  
Here, I used two P. falciparum lines namely, 3D7, the chloroquine sensitive line and Dd2, the 
chloroquine resistant line.  While most of the antimalarials currently in use act on the parasite 
after entry into the erythrocyte, the highly sulfated glycosaminoglycan, heparin inhibits parasite 
entry.  However, heparin use in clinical malaria causes bleeding as side effect. As an alternative, 
compounds with structures similar to heparin, such as heparan sulfate and its low molecular 
weight derivatives, as well as other sulfated polysaccharides, such as fucoidan, dextran sulfate, 
and carrageenans and their derivatives, can be exploited in finding compounds that can inhibit 
parasite entry into the host erythrocyte.   
Gellan sulfate was shown to inhibit the growth and invasion of P. falciparum in vitro.   The 
oversulfated κ- and hydrolyzed λ-carrageenans, however, showed poor inhibition of P. 
falciparum in vitro. These derivatives were also found to be non-cytotoxic based on in vitro 
MTT cytotoxicity assays on 293T cells.  With further interest in gellan sulfate, I performed 
APTT anticoagulant assays in vitro and found that it has low anticoagulant activity.  
In chapter 2, the synthesized gellan sulfate was assessed for its in vivo ability to suppress the 
growth of  P. yoelii 17XL and P. berghei ANKA, in the BALB/c and C57BL/6 mice, 
respectively. Following the 4-day suppressive test, the mice were injected with parasites 
intraperitoneally at day 0 and were given treatments of artesunate, gellan gum and gellan sulfate 
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at various doses by the same route from day 0 to day 3 post-infection.  Parasitemias from day 4 
to day 10 post-infection showed no difference between the control and gellan sulfate treated 
groups.  This suggests that gellan sulfate, which showed good inhibition of growth and invasion 
of P. falciparum 3D7 and Dd2 in vitro, had little effect on the growth of P. yoelii 17XL and P. 
berghei ANKA in vivo. It was also observed that some infected mice that were treated with both 
the native gellan gum and gellan sulfate survived until 30 days post-infection, showing a delay in 
the death of the infected mice. It can be assumed that gellan sulfate may have inhibitory effect 
similar to heparin, on the sequestration and cytoadhesion of infected red blood cells which leads 
to the more serious consequences of malaria, such as cerebral malaria and placental malaria.  
However, it was unclear why the same effect on survival was observed in the group that was 
given native gellan gum because of the limited studies that focus on the physiological effects of 
gellan gum other than it being safe for use as a drug vehicle.   It was also shown here that the 
native gellan gum and gellan sulfate are safe to be given intraperitoneally at dose of up to 
25mg/kg bodyweight but may be toxic at dose of 50mg/kg BW. 
In chapter 3, the effect of λ carrageenan on the development of experimental cerebral 
malaria (ECM) in mice was investigated.  Here, I had intended to show that since λ-carrageenan 
injection in rats has been shown to alter the permeability of the blood brain barrier, experimental 
cerebral malaria may develop in the BALB/c mouse, which is considered resistant to ECM 
caused by P. berghei ANKA.  This is in contrast to the C57BL/6 mouse, which is considered a 
susceptible strain, and in which strain, signs of ECM can be clearly observed and mortality due 
to ECM occurs at day 6 or 7 post infection. 
Following the 4-day suppressive test protocol, λ-carrageenan was given intraperitoneally to 
BALB/c mice infected with P. berghei ANKA.   Carrageenans had been reported to inhibit P. 
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falciparum 3D7 and Dd2 in vitro.  But in this study, parasitemias of the infected mice rose at the 
same rate for the control and λ-carrageenan-treated groups.  This shows that λ-carrageenan had 
little effect on the growth of P. berghei ANKA in vivo. 
The results also showed that the BALB/c mice infected with P.berghei ANKA, both the λ-
carrageenan treated (PbCGN) and untreated groups (PbN), showed leakage of the blood brain 
barrier and histopathologic lesions, such as focal and microhemorrhages in the brain, that are 
used to describe ECM. Clinical signs of cerebral malaria like convulsions and limb paralysis 
were not observed in mice untreated with λ-carrageenan, but signs, which overlap with those of 
severe malaria, were observed for both treatment groups.  These signs included shivering and 
huddling, weakness, and reluctance to move.  Deaths occurred earlier in the λ-carrageenan-
treated group.  The PbCGN mice died within 5 days post-infection after having seizures and 
falling into moribund state.  These results indicate that λ-carrageenan administration exacerbate 
malaria by inducing the development of cerebral malaria leading to acute death of the animal.   
It became interesting for me to study the effects of λ-carrageenan on the possible 
development of cerebral malaria in the BALB/c mice infected with P. berghei ANKA because 
prior to making the modified polysaccharides, I performed in vivo growth inhibition assays on P. 
yoelii 17XL using different sulfated polysaccharides, namely: fucoidan (Sigma, 100mg/kg BW), 
dextran sulfate (Sigma, 20,000MW; 0.01mg/kg BW), heparan sulfate (0.10μg/g BW) and λ-
carrageenan (Sigma, 20mg/kg BW) in BALB/c mice. In the above-mentioned experiments, the 
parasitemia of the infected mice that were treated with the aforementioned sulfated 
polysaccharides were slightly but not significantly lower than that of the untreated mice.  
Survival of the infected mice was not improved by treatment of these polysaccharides as well.  In 
addition, I observed that immediately after injection of fucoidan (100mg/kg) intraperitoneally, 
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the mice huddled together and then had ruffled hair and weight loss.  These signs, which can be 
interpreted as signs of toxicity to the drug, were not reported in the work by Chen et al (2009) 
which used a similar dose of their own preparation of fucoidan.  
In another experiment, I used ι-carrageenan against P. berghei ANKA in BALB/c mice.  
One in three mice died at day 6 post-infection with parasitemia of 6% , while the two others died 
2 weeks later.   This was in spite of ι-carrageenan being considered to be the safest to administer 
intraperitoneally among the 3 types of carrageenan [Thomson and Horne, 1976].   The report that 
λ-carrageenan injection in rats alters the permeability of the blood brain barrier [Huber, 2002] led 
me to hypothesize that the cause of death for that specific mouse was possibly due to the 
development of cerebral malaria. 
 
This also prompted my interest to study as to whether the modification of polysaccharides, 
such as sulfation of κ-carrageenan could lead to antimalarials that inhibit entry of the 
Plasmodium merozoites in vitro, similar to heparin, but are safer for use in clinical malaria. 
 
This work shows that naturally-derived or synthetic novel sulfated polysaccharides are 
promising sources of new antimalarials which have modes of action similar to heparin, inhibiting 
the invasion of red blood cells by the Plasmodium parasites, but with less anticoagulant activity.  
If the invasion process is halted, there is a chance that the immune system targets the free 
Plasmodium merozoites, eventually leading to clearance of the parasites and development of 
immunity against malaria infection.   However, at present, there is yet to be such 
glycosaminoglycan that is safe for use in clinical malaria.  As shown here, gellan sulfate and 
carrageenans which were effective against malaria parasites in vitro were less effective against 
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malaria parasites in vivo.  It was also shown here that carrageenans can also cause severe 
complications during malaria infection.   
The recent work by Mathias et al [Mathias et al 2013] showing the potential of a synthetic 
glycosaminoglycan as a transmission blocking drug, opens another avenue for the application of 
these sulfated polysaccharides on the control of malaria that is worth exploring in the future. 
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論文題目  Studies on the effects of sulfated polysaccharides on malaria infection 
（マラリア感染への硫酸化多糖類の効果に関する研究） 
    
 
 
 
 
 
 
 
 
Malaria is a global concern. Concerted efforts have been geared to eradicate malaria especially in endemic 
areas, which are mostly developing countries. Vaccines that can prevent malaria infection are currently under 
testing while the screening for new antimalarial drugs is also a continuing process. Most of the antimalarial 
drugs that are currently being used during the blood stage of malaria when the Plasmodium parasites have 
already invaded red blood cells (RBCs) and the clinical symptoms of disease, including fever, are already 
presented. So there is a current interest in developing vaccines and drugs that can prevent the invasion of 
RBCs, so that the infection is halted altogether. Heparin is a sulfated glycosaminoglycan that can inhibit the 
entry of the Plasmodium parasites into the RBCs. However, it is not recommended for use in clinical malaria 
for its anticoagulant effects. Other sulfated polysaccharides like carrageenans from seaweeds were shown to 
have the same inhibitory effect on Plasmodium parasites in vitro. But their effect in vivo are not yet extensively 
studied. This work explored a novel anticoagulant, gellan sulfate, derived from the microbial 
polysaccharide,gellan gum, and other derivatives of carrageenans on their effects on the growth and invasion 
of malaria parasites in vitro and in vivo.  
Gellan sulfate and oversulfated κ-carrageenan were prepared by adding DMF-SO3 to gellan gum. λ-
Carrageenan was modified by acid hydrolysis. The sulfation of gellan and κ-carrageenan were determined by 
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nuclear magnetic resonance spectroscopy and the level of sulfation were measured by elemental analysis. 
Gellan sulfate, but not oversulfated κ-carrageenan and hydrolyzed λ-carrageenan, nor the native gellan gum, 
was shown to inhibit the growth and invasion of RBCs by P. falciparum in in vitro inhibition assays.  Gellan 
sulfate was also shown to have low cytotoxicity and anticoagulant effects and thus, it was further assessed in in 
vivo studies using rodent malaria models.  
In the 4-day suppressive test of growth in vivo, BALB/c and C57BL/6 mice were infected with the lethal 
parasites, P. yoelii 17XL and P. berghei ANKA, respectively. Gellan sulfate and native gellan gum were tested 
against artesunate (20mg/kg), an artemisinin derivative which is one of the recommended treatments for severe 
malaria. With various tested doses, of 20, 25, and 50mg/kg given to mice intraperitoneally, gellan sulfate and 
native gellan gum were found to be ineffective in inhibiting growth of the parasites in vivo. The parasitemias 
continued to rise after suppressive treatment and the mice eventually succumbed to the disease from 6 to 30 
days post-infection. In addition, at 50mg/kg, gellan gum and gellan sulfate treated mice were observed to have 
weight loss and ruffled hair. This might indicate that at this dose, gellan gum and gellan sulfate were toxic to 
the mice. 
Carrageenans have been shown to inhibit the growth and invasion of RBCs by P. falciparum in vitro. 
However, λ-carrageenan was also shown to increase the permeability of the blood brain barrier when 
administered to rats. Therefore, the use of carrageenans in malaria may actually cause cerebral malaria (CM). 
In this work, I examined the effect of carrageenans on the development of CM in the BALB/c mouse, 
considered as resistant strain, using P. berghei ANKA, a standard model for experimental CM.  It is found that 
λ-carrageenan (25mg/kg) can induce symptoms and histopathological lesions related to CM.  
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